Key facts
- This page summarizes David Hollander's Form 4 filing for AERIE PHARMACEUTICALS INC.
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 08 Feb 2022, 19:40.
David Hollander - 04 Feb 2022 Form 4 Insider Report for AERIE PHARMACEUTICALS INC
- Reporting relationship
- Chief R&D Officer
- Issuer ticker
- N/A
- Reported as of
- 04 Feb 2022
- Net transaction value
- -$6,535
- SEC form
- 4
- Accepted by SEC
- 08 Feb 2022, 19:40:33 UTC
- Prior SEC filing
- 03 Feb 2022
- Next SEC filing
- 07 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ John LaRocca, Attorney-in-Fact for David Hollander
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David Hollander filed Form 4 for AERIE PHARMACEUTICALS INC on 08 Feb 2022.
Change
- Previous filing in this sequence was filed on 03 Feb 2022.
- Current net transaction value: -$6,535.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AERI
transaction
Common Stock
Tax liability
- Transaction value
- $6,535
- Shares
- -927
- Change %
- -2.9%
- Price
- $7.05
- Shares after
- 30,749
- Date
- 04 Feb 2022
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Reflects shares of Common Stock withheld to satisfy tax withholding obligations in connection with the vesting of shares of restricted Common Stock.